| 8.4017 -0.548 (-6.13%) | 08-18 11:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.49 | 1-year : | 12.25 |
| Resists | First : | 8.98 | Second : | 10.49 |
| Pivot price | 7.88  |
|||
| Supports | First : | 7.74 | Second : | 6.98 |
| MAs | MA(5) : | 8.37 |
MA(20) : | 7.79 |
| MA(100) : | 8.55 |
MA(250) : | 7.75 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 84 |
D(3) : | 76.1 |
| RSI | RSI(14): 59.5  |
|||
| 52-week | High : | 13.67 | Low : | 3.26 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ KYTX ] has closed below upper band by 9.3%. Bollinger Bands are 16.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.99 - 9.02 | 9.02 - 9.05 |
| Low: | 7.93 - 7.96 | 7.96 - 7.99 |
| Close: | 8.89 - 8.94 | 8.94 - 9 |
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Mon, 17 Aug 2026
Kyverna Therapeutics (NASDAQ:KYTX) Trading 6.7% Higher - Should You Buy? - MarketBeat
Mon, 17 Aug 2026
AIGH Capital Management LLC Purchases Shares of 2,795,797 Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Sat, 15 Aug 2026
Walleye Capital LLC Purchases New Shares in Kyverna Therapeutics, Inc. $KYTX - MarketBeat
Fri, 14 Aug 2026
Kyverna Therapeutics (KYTX): Bain Capital fund reports 4.75% ownership stake - Stock Titan
Thu, 13 Aug 2026
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX) - Seeking Alpha
Tue, 11 Aug 2026
Kyverna Therapeutics (KYTX) deepens pipeline with SPS BLA, H1 2026 loss narrows - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 82.1 (%) |
| Shares Short | 7,850 (K) |
| Shares Short P.Month | 6,070 (K) |
| EPS | -3.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.6 % |
| Return on Equity (ttm) | -74.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.08 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -150 (M) |
| Levered Free Cash Flow | -94 (M) |
| PE Ratio | -2.65 |
| PEG Ratio | 0 |
| Price to Book value | 2.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|